mounjaro indication for weight loss
Mounjaro (tirzepatide) is a once-weekly non-insulin injection used to help lower A1C levels in adults with type 2 diabetes, as an addition to diet and exercise. Studies have shown that people taking Mounjaro have experienced significant weight loss when used alongside diet and exercise. In a study of people who were overweight or had obesity, those taking Mounjaro lost an average of 10.7 kg (23.6 lbs) compared to those taking a placebo, who lost an average of only 2.3 kg (5.1 lbs). Additionally, Mounjaro has been shown to improve other metabolic factors such as triglycerides and HDL cholesterol.
mounjaro weight loss side effects
The most common side effects reported by patients taking Mounjaro are nausea, diarrhea, decreased appetite, indigestion, vomiting, constipation, and stomach pain. However, these side effects are usually mild and tend to improve with time. Less common side effects include itching, swelling, and redness at the injection site, tiredness, and loss of appetite. If any of these side effects become severe or do not go away, talk to your doctor or healthcare provider.
 |
| What is mounjaro weight loss? |
mounjaro indication for weight loss
Mounjaro (tirzepatide) is not indicated for weight loss. It is a once-weekly non-insulin injection used to help lower A1C levels in adults with type 2 diabetes, as an addition to diet and exercise. Studies have shown that people taking Mounjaro have experienced significant weight loss when used alongside diet and exercise, but weight loss is not one of its intended indications.
what happens when you stop taking mounjaro?
If you stop taking Mounjaro, your blood sugar levels may rise again. In a study that allowed patients to stop taking Mounjaro after one year, most patients regained the weight they lost, indicating a need to take the medication long-term in order to maintain the weight loss. Additionally, your blood sugar levels may fluctuate while taking Mounjaro, so it is important to continue regular blood sugar monitoring and to take any other medications prescribed by your doctor. If you have any questions or concerns about taking Mounjaro, talk to your doctor or healthcare provider.
when will tirzepatide be approved?
Tirzepatide (Mounjaro) was approved by the US Food and Drug Administration (FDA) in May 2022 for use in adults with type 2 diabetes to help control blood sugar. It is the first once-weekly injectable diabetes medication approved for this purpose.
mounjaro weight loss reviews
Reviews of Mounjaro's effectiveness for weight loss have been generally positive. A study of people with type 2 diabetes who were overweight or had obesity showed that those taking Mounjaro lost an average of 10.7 kg (23.6 lbs) compared to those taking a placebo, who lost an average of only 2.3 kg (5.1 lbs). Additionally, Mounjaro has been shown to improve other metabolic factors such as triglycerides and HDL cholesterol. Reviews from users have also been generally positive with many people noting that Mounjaro has helped them to lose weight and improve their blood sugar control.